Mullan as CEO should now say to Wall Street that Star is a legitimate biotech stock, and the results so far have been impressive. Why else would Mullan leave Roskamp to head up Star going forward. All good as far as I can see.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.